Patents by Inventor Lilach Agemy

Lilach Agemy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONAL THERAPIES FOR TREATMENT OF CANCER COMPRISING A BACTERIOCHLOROPHYLL DERIVATIVE
    Publication number: 20220202838
    Abstract: An anti-myeloid-derived suppressor cells agent (“anti-MDSCs agent”) and a bacteriochlorophyll derivative (hereinafter”Bchl-D) for use in combination therapy for cancer. wherein the anti-MDSC agent and the Bchl-D are administered sequentially and the administration of the Bchl-D is followed by photodynamic therapy (PDT) or vascular targeted PDT (VTP).
    Type: Application
    Filed: March 21, 2022
    Publication date: June 30, 2022
    Inventors: Avigdor SCHERZ, Yoram SALOMON, Lilach AGEMY, Rachel HAMRI, Dina PREISE, Kwanghee KIM, Jonathan COLEMAN
  • Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative
    Patent number: 11278555
    Abstract: An anti-myeloid-derived suppressor cells agent (“anti-MDSCs agent”) and a bacteriochlorophyll derivative (hereinafter “Bchl-D) for use in combination therapy for cancer, wherein the anti-MDSC agent and the Bchl-D are administered sequentially and the administration of the Bchl-D is followed by photodynamic therapy (PDT) or vascular targeted PDT (VTP).
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: March 22, 2022
    Assignees: YEDA RESEARCH AND DEVELOPMENT CO. LTD., MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Avigdor Scherz, Yoram Salomon, Lilach Agemy, Rachel Hamri, Dina Preise, Kwanghee Kim, Jonathan Coleman
  • METHODS AND COMPOSITIONS FOR ENHANCED DELIVERY OF COMPOUNDS
    Publication number: 20170246236
    Abstract: Disclosed are compositions and methods related to multivalent compositions targeted to cells and tissues. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.
    Type: Application
    Filed: December 12, 2016
    Publication date: August 31, 2017
    Inventors: Lilach Agemy, Dinorah Friedmann-Morvinski, Venkata Ramana Kotamraju, Erkki Ruoslahti, Kazuki Sugahara, Inder Verma
  • Methods and compositions related to clot-binding compounds
    Patent number: 8912136
    Abstract: Disclosed are compositions and methods related to clot-binding compounds. For example, disclosed are compositions comprising a surface molecule and at least one modified clot-binding compound. The modified clot-binding compound can selectively bind to clotted plasma protein, wherein the composition causes clotting and amplifies the accumulation of the composition in tumors. The modified clot-binding compound can enhance the clotting in tumors compared to its unmodified derivative. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: December 16, 2014
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Lilach Agemy, Venkata Ramana Kotamraju
  • METHODS AND COMPOSITIONS FOR ENHANCED DELIVERY OF COMPOUNDS
    Publication number: 20110262347
    Abstract: Disclosed are compositions and methods related to multivalent compositions targeted to cells and tissues. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.
    Type: Application
    Filed: April 8, 2011
    Publication date: October 27, 2011
    Inventors: Erkki Ruoslahti, Lilach Agemy, Dinorah Friedmann-Morviniski, Venkata Ramana Kotamraju, Kazuki Sugahara, Inder Verma
  • METHODS AND COMPOSITIONS RELATED TO CLOT-BINDING COMPOUNDS
    Publication number: 20110165064
    Abstract: Disclosed are compositions and methods related to clot-binding compounds. For example, disclosed are compositions comprising a surface molecule and at least one modified clot-binding compound. The modified clot-binding compound can selectively bind to clotted plasma protein, wherein the composition causes clotting and amplifies the accumulation of the composition in tumors. The modified clot-binding compound can enhance the clotting in tumors compared to its unmodified derivative. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.
    Type: Application
    Filed: December 20, 2010
    Publication date: July 7, 2011
    Inventors: Erkki Ruoslahti, Lilach Agemy, Venkata Ramana Kotamraju